◆ NeutralSPRY
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY
GlobeNewswire Inc.·
Rosen Law Firm is notifying investors of ARS Pharmaceuticals (SPRY) about a securities class action lawsuit with an October 5, 2026 lead plaintiff deadline. The lawsuit alleges that ARS Pharmaceuticals provided false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray 'neffy' through CVS Caremark, causing investors to purchase securities at artificially inflated prices.
Read Full Article at GlobeNewswire Inc. →